Y90‐Ibritumomab tiuxetan (Y90‐IT) and high‐dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05) |
| |
| Authors: | Michèle Voegeli Stephanie Rondeau Simona Berardi Vilei Erika Lerch Luciano Wannesson Thomas Pabst Jochen Rentschler Mario Bargetzi Lorenz Jost Nicolas Ketterer Angelika Bischof Delaloye Michele Ghielmini |
| |
| Affiliation: | 1. Medizinische Universit?tsklinik, Liestal, Switzerland;2. SAKK Coordinating Center, Bern, Switzerland;3. Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland;4. Inselspital Bern, Bern, Switzerland;5. Universit?tsspital Basel, Basel, Switzerland;6. Ortenau Klinikum Offenburg, Offenburg, Germany;7. Kantonsspital Aarau, Aarau, Switzerland;8. Kantonsspital Bruderholz, Bruderholz, Switzerland;9. CHUV, Lausanne, Switzerland;10. Hirslanden Lausanne SA, Lausanne, Switzerland |
| |
| Abstract: | Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high‐dose melphalan, on the other hand, has been shown to be safe and active as a pretransplant preparative regimen in elderly patients. Y90‐Ibritumomab tiuxetan (Y90‐IT) is well tolerated and feasible in the transplantation setting. We therefore investigated the combination of high‐dose melphalan and Y90‐IT as a conditioning regimen for patients ≥65 years of age. Patients with relapsed or resistant CD20‐positive lymphoma in remission after salvage chemotherapy could be enrolled. High‐dose therapy consisted of standard dose Y90‐IT (0.4‐mCi/kg body weight) followed by melphalan at escalating doses (100, 140, 170 and 200 mg/m2) and ASCT. The primary objective was to identify the maximum tolerated dose; secondary end points were complete response (CR) rate 100 days after transplantation and toxicity. Twenty patients (median age 72 years) were included. No DLT occurred at any dose level. Thirteen patients completed the treatment, 11 were evaluable for response. Seven patients did not complete treatment because of mobilization failure (n = 3), progressive disease (n = 2), worsening of cardiac function (n = 1), and grade 3 dyspnea (n = 1). Seven patients achieved a CR/complete remission/unconfirmed (CRu) and 2 had stable disease. Five out of 7 responding patients were still alive more than 3 years after transplantation. The 2 patients with SD had a long‐term survival of 3 and 5 years, respectively. Nonhematological grade 3 or higher treatment related adverse events (AEs) were infection (n = 6), including 2 cases of febrile neutropenia, diarrhea (n = 3), mucositis, anorexia, viral hepatitis, hypokalemia, dehydration, and multiorgan failure (n = 1 for each). The combination of Y90‐IT and high‐dose melphalan is feasible before ASCT for elderly patients, with promising activity and manageable toxicity. |
| |
| Keywords: | autologous stem cell transplantation high‐dose melphalan recurrent lymphoma Y90‐Ibritumomab tiuxetan |
|
|
